Back to workflow browser

First-pass extracted concept

minimal framework for precision therapeutic development in silico in monogenic splicing disorders

Candidate: workflow template1 source documents3 linked claims1 workflow observations2 stage observations2 step observations
Jump to workflow stagesJump to workflow logicJump to workflow stepsJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Workflow Stage Observations

Stage 1functional characterizationsequencingSource 1DOIPubMed

multi-omics characterization

Why this stage exists: This stage exists to determine how the splice-site mutation alters RNA processing and protein coding consequences before therapeutic prioritization.

Selection basis: Integrated genomic, transcriptomic, and methylation analysis of the NF1 c.61-2A>G case to resolve pathogenic mechanism.

Advance criteria: Mechanistic consequences of c.61-2A>G are characterized sufficiently to support therapeutic correction assessment.

Enriches for: mechanistic understanding of splice disruption, transcript consequence resolution, epigenetic consequence detection

Preserves downstream axes: therapeutic strategy relevance

Stage 2decision gatein silicoSource 1DOIPubMed

therapeutic correction strategy assessment

Why this stage exists: This stage exists to identify which correction strategy is viable for in vivo use after the mutation mechanism is understood.

Selection basis: Viability of candidate therapeutic correction strategies for in vivo correction.

Advance criteria: A strategy is prioritized if it is viable for in vivo correction.

Decision gate: The abstract states that CRISPR-Cas9 prime editing emerged as the only viable in vivo correction approach.

Higher fidelity: yes

Enriches for: in vivo correction viability

Guards against: non-viable therapeutic strategies

Preserves downstream axes: personalized therapeutic feasibility

Workflow Logic

Workflow evidenceSource 1

Objective: Characterize the pathogenic mechanism of the NF1 c.61-2A>G splice-site mutation and prioritize a viable therapeutic genome-editing correction strategy in silico.

Why it works: The workflow integrates genomic, transcriptomic, and methylation measurements to connect the splice-site variant to aberrant RNA processing and then uses that mechanistic understanding to assess therapeutic correction strategies.

Priority logic: The study first resolves pathogenic mechanism through multi-omics characterization and then evaluates therapeutic correction options, reflecting a mechanism-first prioritization for precision therapy design.

Validation strategy: Use integrated multi-omics evidence to confirm splice disruption, cryptic acceptor usage, transcript truncation consequences, and mutation-associated methylation before assessing therapeutic correction strategies.

Target properties: splice-site consequence resolution, transcript consequence characterization, epigenetic consequence characterization, therapeutic editability for in vivo correction

Target mechanisms: canonical splice acceptor loss, cryptic splice acceptor activation, frameshift and premature stop codon generation, mutation-created CpG methylation

Target techniques: short-read whole genome sequencing, long-read whole genome sequencing, whole transcriptome sequencing, methylation profiling, in silico therapeutic correction strategy assessment

Workflow Step Observations

Step 1analysisSource 1

integrate genomic, transcriptomic, and methylation profiling data for the NF1 c.61-2A>G case

Purpose: Resolve the pathogenic mechanism of the splice-site mutation using complementary omics measurements.

Why now: The abstract frames mechanistic characterization as necessary before therapeutic correction strategies are assessed.

Targets properties: splice consequence resolution, transcript consequence resolution, methylation consequence resolution

Step 2decisionSource 1

assess therapeutic correction strategies and prioritize the viable in vivo approach

Purpose: Determine which therapeutic correction strategy is viable for in vivo correction of the studied splice-site mutation.

Why now: The abstract presents therapeutic assessment after mechanistic multi-omics characterization, implying that mechanism informs strategy prioritization.

Decision gate: Only strategies considered viable for in vivo correction advance; prime editing was selected because it was the only viable approach.

Targets properties: in vivo correction viability

Evidence Snippets

This study provides the first comprehensive multi-omics characterization of the NF1 c.61-2A>G mutation and establishes a minimal framework for precision therapeutic development in silico in monogenic splicing disorders.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1mechanismsupports2026Source 1DOIPubMed

NF1 c.61-2A>G abolishes the canonical splice acceptor site and activates a cryptic splice acceptor 16 nucleotides downstream in exon 2.

Quoted textsource-backed
We confirm that c.61-2A>G abolishes the canonical splice acceptor site, activating a cryptic splice acceptor 16 nucleotides downstream in exon 2.
Claim 2mechanismsupports2026Source 1DOIPubMed

The splicing shift caused by NF1 c.61-2A>G generates a 16-nucleotide deletion that causes a frameshift and premature stop codon truncating the protein N-terminal region.

Quoted textsource-backed
This splicing shift generates a 16-nucleotide deletion, causing a frameshift and premature stop codon that truncates the protein's N-terminal region.
Claim 3study contributionsupports2026Source 1DOIPubMed

The study establishes a minimal framework for precision therapeutic development in silico in monogenic splicing disorders.

Quoted textsource-backed
This study provides the first comprehensive multi-omics characterization of the <i>NF1</i> c.61-2A>G mutation and establishes a minimal framework for precision therapeutic development in silico in monogenic splicing disorders.